AU Patent

AU2016202924A1 — Antisense molecules and methods for treating pathologies

Assigned to University of Western Australia · Expires 2016-05-26 · 10y expired

What this patent protects

H:\ft\interwoven\NRPortbl\DCC\FMT\l0103426_ .docx-6/05/2016 An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 59.

USPTO Abstract

H:\ft\interwoven\NRPortbl\DCC\FMT\l0103426_ .docx-6/05/2016 An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 59.

Drugs covered by this patent

Patent Metadata

Patent number
AU2016202924A1
Jurisdiction
AU
Classification
—
Expires
2016-05-26
Drug substance claim
No
Drug product claim
No
Assignee
University of Western Australia
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.